Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis

Background: Recent clinical trials have demonstrated that tafamidis (Pfizer Inc., New York, NY, USA) reduced all-cause mortality and the number of cardiovascular hospitalizations compared with placebo in patients with transthyretin cardiac amyloidosis. However, the optimal surrogate markers during t...

Full description

Bibliographic Details
Main Authors: Makiko Nakamura, Teruhiko Imamura, Ryuichi Ushijima, Koichiro Kinugawa
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Journal of Clinical Medicine
Subjects:
MGUS
infiltrative cardiomyopathy
electrical dyssynchrony
ATTR-CM
Online Access:https://www.mdpi.com/2077-0383/12/14/4631

Similar Items

Similar Items